597 related articles for article (PubMed ID: 25122186)
1. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Liu L; Pitt B; Pfeffer MA; Solomon SD
Circulation; 2015 Aug; 132(5):402-14. PubMed ID: 26130119
[TBL] [Abstract][Full Text] [Related]
3. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Shah AM; Shah SJ; Anand IS; Sweitzer NK; O'Meara E; Heitner JF; Sopko G; Li G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD;
Circ Heart Fail; 2014 Jan; 7(1):104-15. PubMed ID: 24249049
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
[TBL] [Abstract][Full Text] [Related]
5. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
Santos AB; Roca GQ; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Fang JC; Zile MR; Pitt B; Solomon SD; Shah AM
Circ Heart Fail; 2016 Apr; 9(4):e002763. PubMed ID: 27056882
[TBL] [Abstract][Full Text] [Related]
7. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
[TBL] [Abstract][Full Text] [Related]
8. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
[TBL] [Abstract][Full Text] [Related]
9. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction.
Shin SH; Claggett B; Inciardi RM; Santos ABS; Shah SJ; Zile MR; Pfeffer MA; Shah AM; Solomon SD
J Am Heart Assoc; 2021 Aug; 10(15):e019545. PubMed ID: 34325519
[TBL] [Abstract][Full Text] [Related]
11. Spironolactone for heart failure with preserved ejection fraction.
Pitt B; Pfeffer MA; Assmann SF; Boineau R; Anand IS; Claggett B; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Harty B; Heitner JF; Kenwood CT; Lewis EF; O'Meara E; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; Yang S; McKinlay SM;
N Engl J Med; 2014 Apr; 370(15):1383-92. PubMed ID: 24716680
[TBL] [Abstract][Full Text] [Related]
12. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).
Hegde SM; Claggett B; Shah AM; Lewis EF; Anand I; Shah SJ; Sweitzer NK; Fang JC; Pitt B; Pfeffer MA; Solomon SD
Circulation; 2017 Sep; 136(11):982-992. PubMed ID: 28637881
[TBL] [Abstract][Full Text] [Related]
13. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
[TBL] [Abstract][Full Text] [Related]
15. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
16. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.
Biering-Sørensen T; Shah SJ; Anand I; Sweitzer N; Claggett B; Liu L; Pitt B; Pfeffer MA; Solomon SD; Shah AM
Eur J Heart Fail; 2017 Aug; 19(8):1043-1052. PubMed ID: 28322009
[TBL] [Abstract][Full Text] [Related]
17. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
Cohen JB; Schrauben SJ; Zhao L; Basso MD; Cvijic ME; Li Z; Yarde M; Wang Z; Bhattacharya PT; Chirinos DA; Prenner S; Zamani P; Seiffert DA; Car BD; Gordon DA; Margulies K; Cappola T; Chirinos JA
JACC Heart Fail; 2020 Mar; 8(3):172-184. PubMed ID: 31926856
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; O'Meara E; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Fang JC; Pfeffer MA; Solomon SD
Circ Heart Fail; 2018 Nov; 11(11):e005288. PubMed ID: 30571191
[TBL] [Abstract][Full Text] [Related]
19. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
[TBL] [Abstract][Full Text] [Related]
20. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
